Zimmer Biomet (ZBH) Q1 FY26 earnings call

Zimmer Biomet delivered a strong start to the year, exceeding expectations on sales growth and raising full-year EPS and free cash flow guidance, driven by robust technology sales and new product momentum. The company is confidently progressing with its U.S. go-to-market transformation, despite some expected near-term disruption, and is making strategic investments in innovation and operational efficiency to secure future growth.